MedTrace Logo

Adjuvant High-Dose, Sequential Chemotherapy in Treating Patients With Resected Breast Cancer

NCT00002679 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 89

Last updated 2009-08-26

No results posted yet for this study

Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.

PURPOSE: Phase II trial to study the effectiveness of high-dose sequential chemotherapy as adjuvant therapy in treating patients with stage II or stage III breast cancer who have four or more positive axillary lymph nodes.

Conditions

Interventions

BIOLOGICAL

filgrastim

DRUG

cyclophosphamide

DRUG

doxorubicin hydrochloride

DRUG

paclitaxel

DRUG

tamoxifen citrate

RADIATION

radiation therapy

Sponsors & Collaborators

  • Yale University

    lead OTHER

Principal Investigators

  • Maysa Abu-Khalaf, MD · Yale University

Study Design

Purpose
TREATMENT

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1994-02-28
Primary Completion
2002-01-31
Completion
2002-01-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00002679 on ClinicalTrials.gov